Paediatric patients:
| Dose | Nelarabin | ara - G | |
| Cmax - Plasma | 650 mg/m2 | 45.0 µM | 60.1 µM |
| Vd | 104 - 2,900 mg/m2 | 89.4 L/m2 | 32.1 L/m2 |
| T1/2 | 650 mg/m2 | 30 min | 3 h |
| Cl | 104 - 2,900 mg/m2 | 125 L/h/m2 | 10.8 L/h/m2 |
[SmPC Atriance]
No information is present at this moment.
No information is present at this moment.
| T-ALL, T-LBL |
|---|
|
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
One fatal case of status epilepticus was reported in a child.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific warnings and precautions in children.
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Purine analogues | ||
|---|---|---|
| L01BB06 | ||
| L01BB05 | ||
| L01BB02 | ||
| L01BB03 | ||
| Pyrimidine analogues | ||
|---|---|---|
| L01BC01 | ||
| L01BC52 | ||
| L01BC05 | ||